Prostate Cancer

The FDA Oncologic Drugs Advisory Committee voted 7-1-1 in support of a favorable risk-benefit profile for capivasertib plus abiraterone and prednisone in PTEN-deficient mHSPC.

Findings from the HIFI-2 study suggest that salvage HIFU provides meaningful mid-term oncologic control with an acceptable safety profile in patients with localized prostate cancer recurrence after radiotherapy.

In this episode, Adam B. Weiner, MD, sits down with Giorgio Gandaglia, MD, to discuss the ongoing controversy surrounding pelvic lymph node dissection in prostate cancer.

Phase 1 data on 225Ac–J591 showed encouraging antitumor activity with manageable toxicity in patients with mCRPC.

Data from the CANOPY trial showed promising activity and manageable safety with cabozantinib plus nivolumab in mCRPC.

The trial will assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of JANX014 in patients with mCRPC.

Fred Saad, MD, FRCS, discusses findings from a post hoc analysis of the phase 3 ARANOTE trial.

Daniel J. George, MD, highlights patient-reported outcomes and tolerability findings from the phase 3 CAPItello-281 trial, evaluating the addition of capivasertib to abiraterone in patients with PTEN-deficient de novo mHSPC.

In this episode of The UroOnc Minute, Adam B. Weiner, MD, speaks with Alexander Light, MBBS, about evolving strategies for salvage treatment in patients with radiorecurrent prostate cancer.

Treatment with 177Lu-PSMA-617 may durably delay disease progression compared with deferred ADT in men with oligometastatic hormone-sensitive prostate cancer.

Stacy Loeb, MD, MSc, discusses emerging data on microplastics and prostate cancer and highlights practical steps to reduce plastic exposure.

Daniel George, MD, discusses key efficacy findings from the phase 3 CAPItello-281 trial evaluating capivasertib plus abiraterone vs placebo plus abiraterone in patients with PTEN-deficient metastatic hormone-sensitive prostate cancer.

"Urologists today are armed with 2 guideline-supported modalities to reduce the burden of unnecessary biopsies while maintaining timely detection of clinically significant cancers," write the authors.

The device will be available over the counter in the US, with anticipated availability beginning in April 2026.

At 3 years, transdermal estradiol demonstrated noninferior MFS compared with standard LHRH agonists.

The study is evaluating the safety, tolerability, whole-body distribution, and preliminary clinical activity of RAD 402 in patients with locally advanced or metastatic castration-resistant prostate cancer.

Matthias Saar, MD, discusses findings from the phase 2 INDUCTA study, evaluating the use of inductive hormonal therapy to achieve operability in patients with T4 prostate cancer.

Andrew J. Armstrong, MD, MS, highlights updated recommendations from the Prostate Cancer Working Group 4.

In this episode of The UroOnc Minute, host Adam B. Weiner, MD, is joined by Veeru Kasivisvanathan, MBBS, MSc, PhD, FRCS, to discuss the role of biparametric vs multiparametric MRI for prostate cancer detection.

The European Commission is expected to have a final decision on the application in the second quarter of 2026.

The PRIMARY2 phase 3 trial found that PSMA PET-CT in men with normal or equivocal MRI results safely halved the number of prostate biopsies, maintained non-inferior detection of clinically significant cancer, and reduced insignificant cancer diagnosis by more than half.

Neha Vapiwala, MD, pointed to the shift toward more personalized approaches and the expanding role of radiopharmaceutical therapies.

Topline results from the TALAPRO-3 study showed that adding talazoparib to enzalutamide improved rPFS for patients with HRR-mutated mCSPC.